Track newly launched stocks and recent IPO debuts.
After artificial intelligence became the dominant investment theme of the decade, many technology investors have started looking for the next…
At an IPO price of $135 per share and an implied valuation approaching $1.75 trillion, SpaceX is preparing for what…
Elmet is not simply a metal fabrication company. It sits at the intersection of several of the most strategically important…
Conexeu is attempting to develop biomaterial solutions that can help the body regenerate tissue more effectively. Aging populations, rising cosmetic…
AMSS has lost roughly 50% of its value despite operating in one of the fastest-growing segments of the beverage industry:…
he company entered public markets with the largest IPO of the year, raising over $5.5 billion at an offering price…
While many competitors are still focused on concepts, simulations, and future promises, BETA is already flying aircraft, building charging infrastructure,…
Fervo Energy may be one of the most important IPOs of 2026 because it sits exactly where Wall Street currently…
Between September 2025 and May 2026, about 235 IPOs entered the US market. Thirty-eight of these – roughly one in…
Unlike some recent speculative biotech listings, COAG has a genuine scientific story and unusually strong private backers. But it also…
According to company materials, over 60% of Nasdaq-100 companies are customers, and data centers have become its fastest-growing vertical.
VG already generates billions in revenue, billions in profit, and operates in one of the most strategically important industries in…
The cartilage repair represents a very large global orthopedic opportunity with substantial unmet medical need. Existing treatment approaches such as…
The new clinical results were undeniably impressive. Veradermics reported that VDPHL01 achieved statistically significant improvements across all primary and key…
Rare Earths Americas is not simply another mining company preparing for listing. It is positioning itself as part of a…
In a market crowded with speculative biotech names, Avalyn Pharma Inc. stands out for targeting a specific and high-value niche:…
The company generated nearly $760 million in annual revenue, remains profitable, and technical indicators still point toward a bullish setup.…
Most recent IPOs have followed a familiar pattern: exciting narrative, weak fundamentals, and explosive volatility. Cardinal Infrastructure Group Inc. (CDNL)…
Zero revenue. $70 million in annual losses. Yet a market valuation of nearly $2.7 billion and a stock that has…
Swarmer Inc. shares jumped hundreds of percent—at times nearly 1,000 percent—in a matter of days, becoming one of the most…